<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">lvrach</journal-id><journal-title-group><journal-title xml:lang="ru">Лечащий Врач</journal-title><trans-title-group xml:lang="en"><trans-title>Lechaschi Vrach</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-5175</issn><issn pub-type="epub">2687-1181</issn><publisher><publisher-name>ООО «Издательство "Открытые системы"»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.51793/OS.2024.27.4.009</article-id><article-id custom-type="elpub" pub-id-type="custom">lvrach-1224</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>АКТУАЛЬНАЯ ТЕМА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>TOPICAL THEME</subject></subj-group></article-categories><title-group><article-title>Управление рисками прогрессирования хронической обструктивной болезни легких на амбулаторном этапе с учетом клинического фенотипа и особенностей течения заболевания</article-title><trans-title-group xml:lang="en"><trans-title>Risk management of progression of chronic obstructive pulmonary disease at the outpatient stage, taking into account the clinical phenotype and peculiarities of the course of the disease</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5421-4202</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Таютина</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Tayutina</surname><given-names>T. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Таютина Татьяна Владимировна, к.м.н., доцент кафедры терапии с курсом поликлинической терапии</p><p>344022, Ростов-на-Дону, пер. Нахичеванский, 29</p></bio><bio xml:lang="en"><p>Tatyana V. Tayutina, Cand. Of Sci. (Med.), Associate Professor of the Department of Therapy with a course of outpatient therapy</p><p>29, Nakhichevanskiy lane, Rostov-na-Donu, 344022</p></bio><email xlink:type="simple">tarus76@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Ростовский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Rostov State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>15</day><month>04</month><year>2024</year></pub-date><volume>0</volume><issue>4</issue><fpage>63</fpage><lpage>70</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Таютина Т.В., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Таютина Т.В.</copyright-holder><copyright-holder xml:lang="en">Tayutina T.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.lvrach.ru/jour/article/view/1224">https://journal.lvrach.ru/jour/article/view/1224</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования. Оценить эффективность использования «Программы прогнозирования неблагоприятного исхода, развития сердечно-сосудистых осложнений и эффективности проводимых реабилитационных мероприятий у больных хронической обструктивной болезнью легких (CardioRisk)» (свидетельство о государственной регистрации № RU2023666935, дата регистрации 08.08.2023 г.) для управления рисками прогрессирования хронической обструктивной болезни легких на амбулаторном этапе с учетом клинического фенотипа и особенностей течения заболевания.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Проведен анализ эффективности использования «Программы прогнозирования неблагоприятного исхода, развития сердечно-сосудистых осложнений и эффективности проводимых реабилитационных мероприятий у больных хронической обструктивной болезнью легких (CardioRisk)» у 150 пациентов с данным диагнозом, наблюдающихся амбулаторно по месту жительства и состоящих на диспансерном учете по основному заболеванию. Для оценки эффективности осуществлялось динамическое наблюдение в течение 12 месяцев за пациентами с хронической обструктивной болезнью легких, имеющими высокий и низкий риск неблагоприятного исхода основного заболевания в результате прогнозирования. Анализировали динамику клинических проявлений, количества обострений, переносимости физической нагрузки и прогноза выживаемости по значению индекса BODE.</p></sec><sec><title>Результаты</title><p>Результаты. В группе динамического наблюдения пациентов с низким риском неблагоприятного исхода основного заболевания отмечалось статистически значимое снижение степени выраженности кашля на 4,07% (р = 0,007), отделения мокроты – на 4,72% (р = 0,024). Число обострений в первой группе снизилось на 16,08% (р = 0,05; р = 0,02), индекс BODE – на 9,3% (р = 0,003; р = 0,04), переносимость физической нагрузки увеличилась на 3,7% (р = 0,007). Во второй группе выявлено статистически значимое увеличение степени выраженности одышки на 11,3% (р = 0,04), кашля – на 14,9% (р = 0,022), отделения мокроты – на 27,55% (р = 0,001). Достоверно увеличились количество обострений в течение года – на 12,1% и 8,68% (р = 0,031; р = 0,030) соответственно и индекс BODE – на 15,19% (р = 0,045), что свидетельствовало об ухудшении прогноза в плане выживаемости.</p></sec><sec><title>Заключение</title><p>Заключение. Доказана эффективность использования «Программы прогнозирования неблагоприятного исхода, развития сердечно-сосудистых осложнений и эффективности проводимых реабилитационных мероприятий у больных хронической обструктивной болезнью легких (CardioRisk)» для управления рисками прогрессирования хронической обструктивной болезни легких на амбулаторном этапе с учетом клинического фенотипа и особенностей течения заболевания. Программа решает задачу оптимизации диспансерного наблюдения пациентов с данным диагнозом при оказании первичной медицинской помощи, позволяет провести комплексную оценку индивидуального суммарного риска неблагоприятного исхода основного заболевания. Полученные данные необходимо учитывать при формировании персональной программы реабилитации пациентов с обязательной модификацией образа жизни (отказ от курения и использование альтернативных источников доставки никотина для тех, кто не мотивирован на отказ от курения).</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Objective</title><p>Objective. The purpose of the study is to evaluate the effectiveness of using the "Program for predicting an unfavorable outcome, the development of cardiovascular complications and the effectiveness of rehabilitation measures in patients with chronic obstructive pulmonary disease (CardioRisk)" (Certificate number of state registration RU2023666935, registration date 08.08.2023) to manage the risks of COPD progression at the outpatient stage, taking into account the clinical phenotype and features of the course of the disease.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. The analysis of the effectiveness of the use of the "Program for predicting an unfavorable outcome, the development of cardiovascular complications and the effectiveness of rehabilitation measures in patients with chronic obstructive pulmonary disease (CardioRisk)" in 150 patients with COPD who are observed on an outpatient basis at the place of residence and are registered at the dispensary for the underlying disease. To assess the effectiveness, dynamic monitoring was carried out for 12 months for patients with COPD who have a high and low risk of an unfavorable outcome of the underlying disease as a result of prognosis. The dynamics of clinical manifestations, the number of exacerbations, the tolerance of physical activity and the prognosis of survival by the value of the BODE index were analyzed.</p></sec><sec><title>Results</title><p>Results. In the dynamic follow-up group of patients with a low risk of an unfavorable outcome of the underlying disease, a statistically significant positive degree of cough severity was noted – by 4.07% (p = 0.007), sputum separation - by 4.72% (p = 0.024). The number of exacerbations in the first group decreased by 16.08% (p = 0.05; p = 0.02), the BODE index – by 9.3% (p = 0.003; p = 0.04), exercise tolerance increased by 3.7% (p = 0.007). In the second group, there was a statistically significant increase in the severity of dyspnea by 11.3% (p = 0.04), cough – by 14.9% (p = 0.022), sputum separation – by 27.55% (p = 0.001). The number of exacerbations significantly increased during the year – by 12.1 and 8.68% (p = 0.031; p = 0.030), respectively, the BODE index increased by 15.19% (p = 0.045), which indicated a deterioration in the prognosis in terms of survival.</p></sec><sec><title>Conclusion</title><p>Conclusion. The effectiveness of using the "Program for predicting an unfavorable outcome, the development of cardiovascular complications and the effectiveness of rehabilitation measures in patients with chronic obstructive pulmonary disease (CardioRisk)" (Certificate number of state registration RU2023666935, registration date 08.08.2023) to manage the risks of COPD progression at the outpatient stage, taking into account the clinical phenotype and features of the course of the disease. The program solves the problem of optimizing the dispensary observation of patients with COPD in the provision of primary medical care, allows for a comprehensive assessment of the individual total risk of an unfavorable outcome of the underlying disease. The data obtained should be taken into account for the formation of a personal rehabilitation program for patients with mandatory lifestyle modification (quitting smoking and using alternative methods to combat smoking).</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>хроническая обструктивная болезнь легких</kwd><kwd>управление рисками</kwd><kwd>отказ от курения традиционных сигарет</kwd><kwd>модификация образа жизни</kwd><kwd>источники доставки никотина</kwd><kwd>неблагоприятный исход</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic obstructive pulmonary disease</kwd><kwd>risk management</kwd><kwd>quitting smoking traditional cigarettes</kwd><kwd>lifestyle modification</kwd><kwd>alternative methods of combating smoking</kwd><kwd>adverse outcome</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование проведено в рамках научно-исследовательской работы ФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава России</funding-statement><funding-statement xml:lang="en">The study was conducted within the framework of the research work of the Rostov State Medical University, Ministry of Health of Russia</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2020 REPORT). Available from: www.goldcopd.org. Accessed March 31, 2021.</mixed-citation><mixed-citation xml:lang="en">Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2020 REPORT). Available from: www. goldcopd.org. Accessed March 31, 2021.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Fang L., Gao P., Bao H., et al. Chronic obstructive pulmonary disease in China: a nationwide prevalence study. Lancet Respir Med. 2018; 6 (6): 421-430. DOI: 10.1016/s2213-2600(18)30103-6.</mixed-citation><mixed-citation xml:lang="en">Fang L., Gao P., Bao H., et al. Chronic obstructive pulmonary disease in China: a nationwide prevalence study. Lancet Respir Med. 2018; 6 (6): 421-430. DOI: 10.1016/s2213-2600(18)30103-6.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Rehman A. U., Hassali M. A. A., Muhammad S. A., et al. The economic burden of chronic obstructive pulmonary disease (COPD) in the USA, Europe, and Asia: results from a systematic review of the literature. Expert Rev Pharmacoecon Outcomes Res. 2019: 1-12. DOI: 10.1080/14737167.2020.1678385.</mixed-citation><mixed-citation xml:lang="en">Rehman A. U., Hassali M. A. A., Muhammad S. A., et al. The economic burden of chronic obstructive pulmonary disease (COPD) in the USA, Europe, and Asia: results from a systematic review of the literature. Expert Rev Pharmacoecon Outcomes Res. 2019: 1-12. DOI: 10.1080/14737167.2020.1678385.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Tsiligianni I., Kocks J. W. H. Daytime symptoms of chronic obstructive pulmonary disease: a systematic review. NPJ Prim Care Respir Med. 2020; 30 (1): 1-9. DOI: 10.1038/s41533-020-0163-5.</mixed-citation><mixed-citation xml:lang="en">Tsiligianni I., Kocks J. W. H. Daytime symptoms of chronic obstructive pulmonary disease: a systematic review. NPJ Prim Care Respir Med. 2020; 30 (1): 1-9. DOI: 10.1038/s41533-020-0163-5.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Jen R., Rennard S. I., Sin D. D. Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and metaanalysis. Int J Chron Obstruct Pulmon Dis. 2012; 7: 587-595. DOI: 10.2147/COPD.S32765.</mixed-citation><mixed-citation xml:lang="en">Jen R., Rennard S. I., Sin D. D. Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and metaanalysis. Int J Chron Obstruct Pulmon Dis. 2012; 7: 587-595. DOI: 10.2147/COPD.S32765.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Таютина Т. В., Багмет А. Д., Лысенко А. В. и др. Клиникофункциональные особенности хронической обструктивной болезни легких у больных пожилого возраста в Ростовской области. Успехи геронтологии. 2021; 34 (1): 84-89. DOI: 10.34922/ AE.2021.34.1.011.</mixed-citation><mixed-citation xml:lang="en">Tayutina T. V., Bagmet A. D., Lysenko A. V., et al. Clinical and functional features of chronic obstructive pulmonary disease in elderly patients in the Rostov region. Uspeсhi gerontologii. 2021; 34 (1): 84-89. (In Russ). DOI: 10.34922/AE.2021.34.1.011.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Таютина Т. В. Комплексный подход к реализации этапов легочной реабилитации пациентов с хронической обструктивной болезнью легких: значение модификации образа жизни. Клиницист. 2023; 17 (1): 28-38. DOI: 10.17650/1818-8338-2023-17-1-К689.</mixed-citation><mixed-citation xml:lang="en">Tayutina T. V. An integrated approach to the realization of stages of pulmonary rehabilitation of patients with chronic obstructive pulmonary disease: the importance of lifestyle modification. Klinitsist. 2023; 17 (1): 28-38 (In Russ.). DOI: 10.17650/1818-8338-2023-17-1-K689.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Polosa R., Campagna D., Caponnetto P. What to advise to respiratory patients intending to use electronic cigarettes. Discov Med. 2015; 20 (109): 155-161. PMID: 26463097.</mixed-citation><mixed-citation xml:lang="en">Polosa R., Campagna D., Caponnetto P. What to advise to respiratory patients intending to use electronic cigarettes. Discov Med. 2015; 20 (109): 155-161. PMID: 26463097.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Rabinovich R. A., Louvaris Z., Raste Y., et al. Validity of physical activity monitors during daily life in patients with COPD. Eur Respir J. 2013; 42 (5): 1205-1215. DOI: 10.1183/09031936.00134312.</mixed-citation><mixed-citation xml:lang="en">Rabinovich R. A., Louvaris Z., Raste Y., et al. Validity of physical activity monitors during daily life in patients with COPD. Eur Respir J. 2013; 42 (5): 1205-1215. DOI: 10.1183/09031936.00134312.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Santos C., Santos J., Morais L., et al. Pulmonary rehabilitation in COPD: Effects of two aerobic exercise intensity in patient centered outcomes – a randomized study (Abstract). Chest. 2011; 140 (4 Suppl): 853A. DOI: 10.1378/chest.1119544.</mixed-citation><mixed-citation xml:lang="en">Santos C., Santos J., Morais L., et al. Pulmonary rehabilitation in COPD: Effects of two aerobic exercise intensity in patient centered outcomes – a randomized study (Abstract). Chest. 2011; 140 (4 Suppl): 853A. DOI: 10.1378/chest.1119544.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Farsalinos K. Е., Polosa R. Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: a systematic review. Ther Adv Drug Saf. 2014; 5 (2): 67-86. DOI: 10.1177/2042098614524430.</mixed-citation><mixed-citation xml:lang="en">Farsalinos K. Е., Polosa R. Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: a systematic review. Ther Adv Drug Saf. 2014; 5 (2): 67-86. DOI: 10.1177/2042098614524430.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Farsalinos K. E., Romagna G., Tsiapras D., et al. Characteristics, perceived side effects and benefits of electronic cigarette use: a worldwide survey of more than 19000 consumers. Int J Environ Res Public Health. 2014; 11 (4): 4356-4373. DOI: 10.3390/ijerph110404356. 13. Sutherland E. R., Crapo J. D., Bowler R. P. N-acetylcysteine and exacerbations of chronic obstructive pulmonary disease. СOPD. 2006; 3 (4): 195-202. DOI: 10.1080/15412550600977361.</mixed-citation><mixed-citation xml:lang="en">Farsalinos K. E., Romagna G., Tsiapras D., et al. Characteristics, perceived side effects and benefits of electronic cigarette use: a worldwide survey of more than 19000 consumers. Int J Environ Res Public Health. 2014; 11 (4): 4356-4373. DOI: 10.3390/ijerph110404356. 13. Sutherland E. R., Crapo J. D., Bowler R. P. N-acetylcysteine and exacerbations of chronic obstructive pulmonary disease. СOPD. 2006; 3 (4): 195-202. DOI: 10.1080/15412550600977361.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Polosa R., Morjaria J., Prosperini U., et al. Health outcomes in COPD smokers using heated tobacco products: a 3-year follow-up. Intern Emerg Med. 2021; 16 (3): 687-696. DOI: 10.1007/s11739-021-02674-3.</mixed-citation><mixed-citation xml:lang="en">Polosa R., Morjaria J., Prosperini U., et al. Health outcomes in COPD smokers using heated tobacco products: a 3-year follow-up. Intern Emerg Med. 2021; 16 (3): 687-696. DOI: 10.1007/s11739-021-02674-3.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Steer J., Gibson J., Bourke S. C. The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. Thorax. 2012; 67 (11): 970-976. DOI: 10.1136/thoraxjnl-2012-202103.</mixed-citation><mixed-citation xml:lang="en">Steer J., Gibson J., Bourke S. C. The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. Thorax. 2012; 67 (11): 970-976. DOI: 10.1136/thoraxjnl-2012-202103.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Suissa S., Dell'Aniello S., Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012; 67 (11): 957-963. DOI: 10.1136/thoraxjnl-2011-201518.</mixed-citation><mixed-citation xml:lang="en">Suissa S., Dell'Aniello S., Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012; 67 (11): 957-963. DOI: 10.1136/thoraxjnl-2011-201518.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Vestbo J., Hurd S. S., Agust A. G., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013; 187 (4): 347-365. DOI: 10.1164/rccm.201204-0596PP.</mixed-citation><mixed-citation xml:lang="en">Vestbo J., Hurd S. S., Agust A. G., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013; 187 (4): 347-365. DOI: 10.1164/rccm.201204-0596PP.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Chen M., Li H., Fan H., et al. ConCeptCNN: A novel multi-filter convolutional neural network for the prediction of neurodevelopmental disorders using brain connectome. Med. Physics. 2022; 49 (5): 3171-3184. DOI: 10.1002/mp.15545.</mixed-citation><mixed-citation xml:lang="en">Chen M., Li H., Fan H., et al. ConCeptCNN: A novel multi-filter convolutional neural network for the prediction of neurodevelopmental disorders using brain connectome. Med. Physics. 2022; 49 (5): 3171-3184. DOI: 10.1002/mp.15545.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Chung C. C., Chan L., Bamodu O. A., Hong C. T., Chiu H. W. Artificial neural network-based prediction of postthrombolysis intracerebral hemorrhage and death. Sci Rep. 2020; 10 (1): 20501. DOI: 10.1038/s41598-020-77546-5. PMID: 33239681; PMCID: PMC7689530.</mixed-citation><mixed-citation xml:lang="en">Chung C. C., Chan L., Bamodu O. A., Hong C. T., Chiu H. W. Artificial neural network-based prediction of postthrombolysis intracerebral hemorrhage and death. Sci Rep. 2020; 10 (1): 20501. DOI: 10.1038/s41598-020-77546-5. PMID: 33239681; PMCID: PMC7689530.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Morjaria J. B., Campagna D., Grazia C., Renee O’Leary, Riccardo Polosa. Health impact of e-cigarettes and heated tobacco products in chronic obstructive pulmonary disease: current and emerging evidence. Expert Review of Respiratory Medicine. 2022; 16: 11-12, 1213-1226. DOI: 10.1080/17476348.2023.2167716.</mixed-citation><mixed-citation xml:lang="en">Morjaria J. B., Campagna D., Grazia C., Renee O’Leary, Riccardo Polosa. Health impact of e-cigarettes and heated tobacco products in chronic obstructive pulmonary disease: current and emerging evidence. Expert Review of Respiratory Medicine. 2022; 16: 11-12, 1213-1226. DOI: 10.1080/17476348.2023.2167716.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Sharman А., Yermakova I., Erenchina E., Tyulebekova G., Bekzhanova A. Respiratory Function and Physical Capacity in Combustible Cigarettes and Heated Tobacco Products Users: a Two-Year Follow-Up Cohort Study. Global Journal of Respiratory Care. 2021; 7: 27-34. DOI: https://doi.org/10.12974/2312-5470.2021.07.05.</mixed-citation><mixed-citation xml:lang="en">Sharman А., Yermakova I., Erenchina E., Tyulebekova G., Bekzhanova A. Respiratory Function and Physical Capacity in Combustible Cigarettes and Heated Tobacco Products Users: a Two-Year Follow-Up Cohort Study. Global Journal of Respiratory Care. 2021; 7: 27-34. DOI: https://doi.org/10.12974/2312-5470.2021.07.05.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
